{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:58:19Z","timestamp":1789988299462,"version":"4.0.1"},"reference-count":71,"publisher":"Impact Journals, LLC","issue":"58","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,11,17]]},"DOI":"10.18632\/oncotarget.22131","type":"journal-article","created":{"date-parts":[[2017,10,30]],"date-time":"2017-10-30T19:23:05Z","timestamp":1509391385000},"page":"98931-98944","source":"Crossref","is-referenced-by-count":26,"title":["<i>CD24<\/i>, <i>CD27<\/i>, <i>CD36<\/i> and <i>CD302<\/i> gene expression for outcome prediction in patients with multiple myeloma"],"prefix":"10.18632","volume":"8","author":[{"given":"Elina","family":"Alaterre","sequence":"first","affiliation":[{"name":"HORIBA Medical, Parc Eurom\u00e9decine, Montpellier, France"},{"name":"Institute of Human Genetics, CNRS-UM UMR9002, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Raimbault","sequence":"additional","affiliation":[{"name":"HORIBA Medical, Parc Eurom\u00e9decine, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik V, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany"},{"name":"Nationales Centrum f\u00fcr Tumorerkrankungen, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salahedine","family":"Bouhya","sequence":"additional","affiliation":[{"name":"CHU Montpellier, Department of Clinical Hematology, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilhem","family":"Requirand","sequence":"additional","affiliation":[{"name":"Department of Biological Haematology, CHU Montpellier, Montpellier, France"},{"name":"Institute of Human Genetics, CNRS-UM UMR9002, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Robert","sequence":"additional","affiliation":[{"name":"Department of Biological Haematology, CHU Montpellier, Montpellier, France"},{"name":"Institute of Human Genetics, CNRS-UM UMR9002, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Boireau","sequence":"additional","affiliation":[{"name":"Department of Biological Haematology, CHU Montpellier, Montpellier, France"},{"name":"Institute of Human Genetics, CNRS-UM UMR9002, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Seckinger","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik V, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany"},{"name":"Nationales Centrum f\u00fcr Tumorerkrankungen, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik V, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Germany"},{"name":"Nationales Centrum f\u00fcr Tumorerkrankungen, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Klein","sequence":"additional","affiliation":[{"name":"Department of Biological Haematology, CHU Montpellier, Montpellier, France"},{"name":"Institute of Human Genetics, CNRS-UM UMR9002, Montpellier, France"},{"name":"University of Montpellier, UFR Medecine, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Moreaux","sequence":"additional","affiliation":[{"name":"Department of Biological Haematology, CHU Montpellier, Montpellier, France"},{"name":"Institute of Human Genetics, CNRS-UM UMR9002, Montpellier, France"},{"name":"University of Montpellier, UFR Medecine, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,10,30]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","article-title":"Multiple myeloma","volume":"374","author":"Anderson","year":"2009","journal-title":"Lancet"},{"key":"2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1634\/theoncologist.2012-0113","article-title":"Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data","volume":"18","author":"Henk","year":"2013","journal-title":"Oncologist"},{"key":"3","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1517\/14712598.2014.908848","article-title":"Monoclonal antibodies currently in Phase II and III trials for multiple myeloma","volume":"14","author":"Palumbo","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/leu.2011.214","article-title":"Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma","volume":"26","author":"Lokhorst","year":"2012","journal-title":"Leukemia"},{"key":"5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3324\/haematol.11080","article-title":"Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders","volume":"93","author":"Mateo","year":"2008","journal-title":"Haematologica"},{"key":"6","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1309\/AJCP1GYI7EHQYUYK","article-title":"Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma","volume":"132","author":"Jain","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"7","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/j.1365-2141.2010.08121.x","article-title":"Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders","volume":"149","author":"Hajek","year":"2010","journal-title":"Br J Haematol"},{"key":"8","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1309\/5EL22BH45PHUPM8P","article-title":"Immunophenotypic differentiation between neoplastic plasma cells in mature B-cell lymphoma vs plasma cell myeloma","volume":"127","author":"Karandikar","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.leukres.2013.12.007","article-title":"Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases","volume":"38","author":"Mulquin","year":"2014","journal-title":"Leuk Res"},{"key":"10","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3109\/10428194.2014.931951","article-title":"Neoplastic plasma cell aberrant antigen expression patterns and their association with genetic abnormalities","volume":"56","author":"Zhan","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"11","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1182\/blood-2006-06-029355","article-title":"CD200 is a new prognostic factor in multiple myeloma","volume":"108","author":"Rossi","year":"2006","journal-title":"Blood"},{"key":"12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.bbrc.2007.11.103","article-title":"CD200: a putative therapeutic target in cancer","volume":"366","author":"Klein","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"13","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1309\/AJCP3TQR1TFHHGAS","article-title":"CD200 expression in plasma cells of nonmyeloma immunoproliferative disorders: clinicopathologic features and comparison with plasma cell myeloma","volume":"138","author":"Kroft","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"14","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1182\/blood-2008-06-161281","article-title":"Regulation of multiple myeloma survival and progression by CD1d","volume":"113","author":"Karadimitris","year":"2009","journal-title":"Blood"},{"key":"15","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1038\/leu.2012.141","article-title":"Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells","volume":"26","author":"Weissman","year":"2012","journal-title":"Leukemia"},{"key":"16","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/j.1365-2141.2007.06729.x","article-title":"Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma","volume":"138","author":"Rasmussen","year":"2007","journal-title":"Br J Haematol"},{"key":"17","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1080\/10428190500467784","article-title":"High expression of CD59 and CD55 on benign and malignant plasma cells","volume":"47","author":"Witzig","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"18","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/ni1440","article-title":"FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis","volume":"8","author":"Smith","year":"2007","journal-title":"Nat Immunol"},{"key":"19","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.4049\/jimmunol.1301430","article-title":"Immunotherapy targeting inhibitory Fcgamma receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization","volume":"191","author":"Glennie","year":"2013","journal-title":"J Immunol"},{"key":"20","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1182\/blood-2007-11-125526","article-title":"CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy","volume":"111","author":"Boruchov","year":"2008","journal-title":"Blood"},{"key":"21","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1182\/blood-2014-07-590166","article-title":"Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction","volume":"125","author":"Owen","year":"2015","journal-title":"Blood"},{"key":"22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3389\/fimmu.2014.00137","article-title":"Immunophenotype of normal and myelomatous plasma-cell subsets","volume":"5","author":"Bene","year":"2014","journal-title":"Front Immunol"},{"key":"23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3324\/haematol.2011.060632","article-title":"Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells","volume":"98","author":"Orfao","year":"2013","journal-title":"Haematologica"},{"key":"24","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3324\/haematol.2011.046821","article-title":"Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma","volume":"97","author":"Klein","year":"2012","journal-title":"Haematologica"},{"key":"25","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Pineda-Roman","year":"2006","journal-title":"Blood"},{"key":"26","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Morgan","year":"2005","journal-title":"J Clin Oncol"},{"key":"27","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Epstein","year":"2007","journal-title":"Blood"},{"key":"28","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1200\/JCO.2007.13.8545","article-title":"Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome","volume":"26","author":"Minvielle","year":"2008","journal-title":"J Clin Oncol"},{"key":"29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3324\/haematol.2010.030296","article-title":"Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma","volume":"96","author":"Neben","year":"2011","journal-title":"Haematologica"},{"key":"30","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/bioinformatics\/btt124","article-title":"Modeling risk stratification in human cancer","volume":"29","author":"Klein","year":"2013","journal-title":"Bioinformatics"},{"key":"31","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Mesirov","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"32","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1182\/blood-2013-06-510453","article-title":"Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile","volume":"122","author":"Garcia-Sanz","year":"2013","journal-title":"Blood"},{"key":"33","first-page":"1577","article-title":"CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy","volume":"91","author":"Owen","year":"2006","journal-title":"Haematologica"},{"key":"34","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/j.1440-1827.2009.02448.x","article-title":"Frequent downregulation or loss of CD79a expression in plasma cell myelomas: potential clue for diagnosis","volume":"59","author":"Yoshino","year":"2009","journal-title":"Pathol Int"},{"key":"35","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1096\/fj.06-6610com","article-title":"Overexpression of tetraspanins affects multiple myeloma cell survival and invasive potential","volume":"21","author":"Lishner","year":"2007","journal-title":"FASEB J"},{"key":"36","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/cyto.b.21279","article-title":"Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents","volume":"90","author":"Omede","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"key":"37","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/(SICI)1521-4141(199904)29:04<1086::AID-IMMU1086>3.0.CO;2-X","article-title":"AIM, a murine apoptosis inhibitory factor, induces strong and sustained growth inhibition of B lymphocytes in combination with TGF-beta1","volume":"29","author":"Miyazaki","year":"1999","journal-title":"Eur J Immunol"},{"key":"38","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1189\/jlb.3RU0215-074R","article-title":"AIM\/CD5L: a key protein in the control of immune homeostasis and inflammatory disease","volume":"98","author":"Sarrias","year":"2015","journal-title":"J Leukoc Biol"},{"key":"39","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood.V76.9.1739.1739","article-title":"Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry","volume":"76","author":"Loken","year":"1990","journal-title":"Blood"},{"key":"40","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1182\/blood.V76.2.377.377","article-title":"Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19)","volume":"76","author":"Grogan","year":"1990","journal-title":"Blood"},{"key":"41","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/BF01697400","article-title":"Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells","volume":"64","author":"Deicher","year":"1992","journal-title":"Ann Hematol"},{"key":"42","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF00920634","article-title":"Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma","volume":"13","author":"Fridman","year":"1993","journal-title":"J Clin Immunol"},{"key":"43","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3109\/10428199909058404","article-title":"Soluble CD16 in plasma cell dyscrasias","volume":"32","author":"Sautes","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"44","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00277-012-1652-6","article-title":"Tumor-associated macrophages as a prognostic parameter in multiple myeloma","volume":"92","author":"Haznedar","year":"2013","journal-title":"Ann Hematol"},{"key":"45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/ejh.12296","article-title":"Monocyte\/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma","volume":"93","author":"Andersen","year":"2014","journal-title":"Eur J Haematol"},{"key":"46","doi-asserted-by":"publisher","first-page":"e425","DOI":"10.1038\/cddis.2012.164","article-title":"CD99 ligation upregulates HSP70 on acute lymphoblastic leukemia cells and concomitantly increases NK cytotoxicity","volume":"3","author":"Dworzak","year":"2012","journal-title":"Cell Death Dis"},{"key":"47","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3389\/fcell.2016.00146","article-title":"CD24: a rheostat that modulates cell surface receptor signaling of diverse receptors","volume":"4","author":"Christian","year":"2016","journal-title":"Front Cell Dev Biol"},{"key":"48","first-page":"3224","article-title":"No expansion of the pre-B and B-cell compartments in the bone marrow of patients with multiple myeloma","volume":"51","author":"Klein","year":"1991","journal-title":"Cancer Res"},{"key":"49","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1182\/blood.V73.2.566.566","article-title":"Phenotypic analysis of human myeloma cell lines","volume":"73","author":"Bataille","year":"1989","journal-title":"Blood"},{"key":"50","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1093\/annonc\/mdr620","article-title":"Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness","volume":"23","author":"Cheson","year":"2012","journal-title":"Ann Oncol"},{"key":"51","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/onc.2013.31","article-title":"CD84 is a survival receptor for CLL cells","volume":"33","author":"Herishanu","year":"2014","journal-title":"Oncogene"},{"key":"52","doi-asserted-by":"publisher","first-page":"23128","DOI":"10.18632\/oncotarget.7440","article-title":"Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?","volume":"7","author":"Menu","year":"2016","journal-title":"Oncotarget"},{"key":"53","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1182\/blood-2009-03-211920","article-title":"Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease","volume":"114","author":"Dhodapkar","year":"2009","journal-title":"Blood"},{"key":"54","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/cmi.2010.35","article-title":"Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells","volume":"8","author":"Qin","year":"2011","journal-title":"Cell Mol Immunol"},{"key":"55","first-page":"920","article-title":"Heterogeneous expression of CD32 and CD32-mediated growth suppression in human myeloma cells","volume":"91","author":"Kawano","year":"2006","journal-title":"Haematologica"},{"key":"56","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/intimm\/dxm100","article-title":"Investigating the functional role of CD2BP2 in T cells","volume":"19","author":"Freund","year":"2007","journal-title":"Int Immunol"},{"key":"57","doi-asserted-by":"publisher","first-page":"e61213","DOI":"10.1371\/journal.pone.0061213","article-title":"CD109 plays a role in osteoclastogenesis","volume":"8","author":"Glogauer","year":"2013","journal-title":"PLoS One"},{"key":"58","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1189\/jlb.0107035","article-title":"Novel human CD4+ T lymphocyte subpopulations defined by CD300a\/c molecule expression","volume":"82","author":"Hart","year":"2007","journal-title":"J Leukoc Biol"},{"key":"59","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1002\/eji.201343433","article-title":"The interaction between CD300a and phosphatidylserine inhibits tumor cell killing by NK cells","volume":"43","author":"Mandelboim","year":"2013","journal-title":"Eur J Immunol"},{"key":"60","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.yexcr.2011.02.016","article-title":"Down-regulation of transcobalamin receptor TCblR\/CD320 by siRNA inhibits cobalamin uptake and proliferation of cells in culture","volume":"317","author":"Quadros","year":"2011","journal-title":"Exp Cell Res"},{"key":"61","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.4236\/jct.2013.46122","article-title":"Saporin conjugated monoclonal antibody to the transcobalamin receptor TCblR\/CD320 is effective in targeting and destroying cancer cells","volume":"4","author":"Sequeira","year":"2013","journal-title":"J Cancer Ther"},{"key":"62","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.biochi.2013.02.004","article-title":"Cellular uptake of cobalamin: transcobalamin and the TCblR\/CD320 receptor","volume":"95","author":"Sequeira","year":"2013","journal-title":"Biochimie"},{"key":"63","doi-asserted-by":"publisher","first-page":"6462","DOI":"10.1038\/onc.2008.312","article-title":"Apoptotic signaling by c-MYC","volume":"27","author":"Liebermann","year":"2008","journal-title":"Oncogene"},{"key":"64","doi-asserted-by":"publisher","first-page":"602","DOI":"10.3109\/10428194.2014.924116","article-title":"Chromosome 8q24.1\/c-MYC abnormality: a marker for high-risk myeloma","volume":"56","author":"Qazilbash","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"65","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/blood.V128.22.115.115","article-title":"Translocations and jumping rearrangements at 8q24 result in over-expression of MYC and are key drivers of disease progression","volume":"128","author":"Morgan","year":"2016","journal-title":"Blood"},{"key":"66","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2004-11-4512","article-title":"The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature","volume":"106","author":"Fiol","year":"2005","journal-title":"Blood"},{"key":"67","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1158\/1535-7163.MCT-12-0721","article-title":"Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors","volume":"11","author":"Klein","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"68","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1038\/leu.2012.127","article-title":"A gene expression signature for high-risk multiple myeloma","volume":"26","author":"van Duin","year":"2012","journal-title":"Leukemia"},{"key":"69","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1182\/blood-2006-09-044974","article-title":"Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib","volume":"109","author":"Sonneveld","year":"2007","journal-title":"Blood"},{"key":"70","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3324\/haematol.2010.033456","article-title":"A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines","volume":"96","author":"Pellat-Deceunynck","year":"2011","journal-title":"Haematologica"},{"key":"71","doi-asserted-by":"publisher","first-page":"e1004077","DOI":"10.1371\/journal.pcbi.1004077","article-title":"GenomicScape: an easy-to-use web tool for gene expression data analysis. Application to investigate the molecular events in the differentiation of B cells into plasma cells","volume":"11","author":"Klein","year":"2015","journal-title":"PLoS Comput Biol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.22131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T14:40:11Z","timestamp":1589208011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.22131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,30]]},"references-count":71,"journal-issue":{"issue":"58","published-print":{"date-parts":[[2017,11,17]]}},"alternative-id":["22131","29228738"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.22131","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,30]]}}}